human jurkat cell line  (ATCC)

Journal: BMC Research Notes

Article Title: A genome-wide CRISPR/Cas9 screen reveals novel positive regulators of FTY720 sensitivity in acute lymphoblastic leukemia cells

doi: 10.1186/s13104-026-07654-4

Figure Lengend Snippet: Cell viabilities of Jurkat wild-type (Jurkat WT) cells and Jurkat cells stably expressing Cas9 (Jurkat-Cas9) treated with different concentrations of FTY720. (A) 24-hour and (B) 48-hour treatment timepoint. The % of cell viability was calculated in comparison to the non-treated control (Control). Data are expressed as mean ± S.D. (error bars) from 2 independent experiments. Control = non-treated control; DMSO = vehicle control

Article Snippet: Jurkat cells stably expressing Cas9 (Genecopoeia, Rockville, MD, catalog no. SL555) were grown following the manufacturer’s protocol.

Techniques: Stable Transfection, Expressing, Comparison, Control

Journal: BMC Research Notes

Article Title: A genome-wide CRISPR/Cas9 screen reveals novel positive regulators of FTY720 sensitivity in acute lymphoblastic leukemia cells

doi: 10.1186/s13104-026-07654-4

Figure Lengend Snippet: Genome-wide CRISPR/Cas9 screen for positive regulators of the FTY720 compared to DMSO (vehicle control) samples. (A) Ranking of positively selected sgRNAs of genes from the MAGeCK-VISPR analysis. The x-axis indicates the positive ranking of individual genes, and the y-axis indicates the values of the corresponding robust ranking aggregation (RRA) score. The top 10 sgRNAs of genes are highlighted and labeled. Two independent screens were performed. (B-K) The read counts (y-axis) and samples (DMSO vs . FTY720 treatment) are shown for the positively selected sgRNAs of genes (B) ZNF575 , (C) GPX3 , (D) FBXL15 , (E) DNAJB5 , (F) UBE2D1 , (G) ATXN7 , (H) C6orf201 , (I) RIC8A , (J) RAB13 and (K) C10orf12 . RRA = robust ranking aggregation score, sgRNA = single-guide RNAs

Article Snippet: Jurkat cells stably expressing Cas9 (Genecopoeia, Rockville, MD, catalog no. SL555) were grown following the manufacturer’s protocol.

Techniques: Genome Wide, CRISPR, Control, Labeling

Journal: bioRxiv

Article Title: Beta-2-microglobulin stimulates neutrophil phagocytosis of bacteria and apoptotic cells

doi: 10.1101/2025.10.30.685267

Figure Lengend Snippet: Efferocytosis of apoptotic Jurkat cells labeled with CellTrace™ Violet by CD66b-positive granulocytes stained with CellTrace™ Far Red was examined under various conditions. (A) PMNs were exposed to varying concentrations of β2m or dK58β2m in the presence of apoptotic Jurkat cells. (B) PMNs were treated with apoptotic cells alone or in combination with 50 µg/ml β2m, 50 µg/ml dK58β2m, 100 ng/ml GM-CSF, or combinations thereof. (C-D) PMNs were treated with apoptotic Jurkat cells with 50 µg/ml β2m (C) or dK58β2m (D) combined with 10 or 25% human AB serum. In all experiments, a 4:1 apoptotic cell-to-PMN ratio was used. Treatment with 100 ng/ml GM-CSF served as a positive control, and pre-incubation with 10 µg/ml cytochalasin D (cyto D) served as a negative control. Results are shown as mean ± SD of double-positive PMNs. Sample sizes were n=6 or n=4 (A), n=10 (B), and n=8 or 3 donors (C and D). Group comparisons were analyzed using mixed-effects analysis and Tukey’s multiple comparisons test (A, C, and D) or repeated-measures ANOVA and Tukey’s multiplecomparisons test(B). Statistical significance is indicated by *P < 0.05 and **P < 0.01, ***P < 0.001, ****P < 0.0001.

Article Snippet: The human T lymphoblast cell line Jurkat (TIB-152TM, ATCC®) was cultured in RPMI 1640 medium supplemented with 1% L-glutamine, 1% penicillin and streptomycin, and 10% fetal bovine serum (FBS; Corning, #35–079-CV) at 37°C with 5% CO 2 .

Techniques: Labeling, Staining, Positive Control, Incubation, Negative Control